Catalyst
Slingshot members are tracking this event:
Dynavax Technologies (DVAX) to finish Phase 1/2 study of SD-101 in combination With Localized Low-dose Radiation in patients with untreated Low-grade B-cell Lymphoma in April 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| DVAX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 18, 2016
Occurred Source:
http://investors.dynavax.com/releasedetail.cfm?ReleaseID=965616
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Sd-101, Phase 1/2 Study, Phase 1 Study, B-cell Lymphoma-2
